当前位置: X-MOL 学术Egypt. J. Bronchol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Respiratory coinfections in COVID-19 patients evaluated by BioFire Pneumonia Panel
The Egyptian Journal of Bronchology ( IF 1.0 ) Pub Date : 2021-06-24 , DOI: 10.1186/s43168-021-00077-8
Hebatallah Hany Assal , Maged Salah , Ayman Kamal Ibrahim , Mostafa Alfishawy , Rawia Khater , Hossam Hosny Masoud , Ahmed Monier Eldemerdash , Mohamed Ali AbdelHalim

Routine administration of antibacterials in patients with Covid-19 has been a subject of debate, with no solid data about the true prevalence of respiratory coinfections in Covid-19 patients in different geographic areas. The aim of the current study was to identify respiratory coinfections in Covid-19 patients admitted to the hospital and to identify its genetic resistance pattern using the respiratory multiplex polymerase chain reaction (PCR). The study included 40 patients, 32 males (80%) and 8 (20%) females with a mean age of 59.3 ± 12.6. Half of the patients had respiratory bacterial coinfections documented by pneumonia (PN) panel. The most common isolate was Klebsiella pneumoniae (10/20, 50%), followed by Acinetobacter calcoaceticus baumanni complex (7/20, 35%). Regarding genetic resistance, thirteen (13/20, 65%) isolates were proven extended spectrum beta lactamase (ESBL)-producing Enterobacteriaceae. Thirteen (13/20, 65%) isolates were proven carbapenemase-producing organisms testing positive for New Delhi metallo-β-lactamase (NDM), oxacillinase β-lactamases (OXA-48), and Verona Integron-Encoded Metallo-β-Lactamase (VIM) (7/20, 35%; 5/20, 25%; 1/20, 5%, respectively). The four isolated Staphylococcus aureus were methicillin-resistant (4/20, 20%). In our cohort, there was 50% rate of bacterial respiratory coinfection in patients with severe Covid-19 admitted to the ICU with high rates of carbapenemase-producing gram-negative bacteria that required escalation of antibacterials and represented a challenge to clinicians.

中文翻译:

BioFire 肺炎专家组评估的 COVID-19 患者的呼吸道合并感染

在 Covid-19 患者中常规使用抗菌药物一直是一个有争议的话题,没有关于不同地理区域 Covid-19 患者呼吸道合并感染真实流行率的可靠数据。本研究的目的是确定入院的 Covid-19 患者的呼吸道合并感染,并使用呼吸道多重聚合酶链反应 (PCR) 确定其遗传耐药模式。该研究包括 40 名患者,其中 32 名男性 (80%) 和 8 名 (20%) 女性,平均年龄为 59.3 ± 12.6。一半的患者有肺炎 (PN) 小组记录的呼吸道细菌合并感染。最常见的分离株是肺炎克雷伯菌 (10/20, 50%),其次是醋酸钙鲍曼尼复合体 (7/20, 35%)。关于遗传抗性,十三 (13/20, 65%) 分离株被证明是产超广谱 β 内酰胺酶 (ESBL) 的肠杆菌科细菌。13 个 (13/20, 65%) 分离株被证明是产碳青霉烯酶的微生物,新德里金属-β-内酰胺酶 (NDM)、苯唑西林酶 β-内酰胺酶 (OXA-48) 和维罗纳整合子编码的金属-β-内酰胺酶呈阳性(VIM)(分别为 7/20、35%;5/20、25%;1/20、5%)。四个分离的金黄色葡萄球菌对甲氧西林耐药(4/20,20%)。在我们的队列中,入住 ICU 的重症 Covid-19 患者的细菌性呼吸道合并感染率为 50%,产碳青霉烯酶的革兰氏阴性菌的发生率很高,这需要增加抗菌药物的用量,这对临床医生来说是一个挑战。65%) 分离株是产碳青霉烯酶的微生物,新德里金属-β-内酰胺酶 (NDM)、苯唑西林酶 β-内酰胺酶 (OXA-48) 和维罗纳整合子编码的金属-β-内酰胺酶 (VIM) 检测呈阳性 (7/ 20, 35%; 5/20, 25%; 1/20, 5%)。四个分离的金黄色葡萄球菌对甲氧西林耐药(4/20,20%)。在我们的队列中,入住 ICU 的重症 Covid-19 患者的细菌性呼吸道合并感染率为 50%,产碳青霉烯酶的革兰氏阴性菌的发生率很高,这需要增加抗菌药物的用量,这对临床医生来说是一个挑战。65%) 分离株是产碳青霉烯酶的微生物,新德里金属-β-内酰胺酶 (NDM)、苯唑西林酶 β-内酰胺酶 (OXA-48) 和维罗纳整合子编码的金属-β-内酰胺酶 (VIM) 检测呈阳性 (7/ 20, 35%; 5/20, 25%; 1/20, 5%)。四个分离的金黄色葡萄球菌对甲氧西林耐药(4/20,20%)。在我们的队列中,入住 ICU 的重症 Covid-19 患者的细菌性呼吸道合并感染率为 50%,产碳青霉烯酶的革兰氏阴性菌的发生率很高,这需要增加抗菌药物的用量,这对临床医生来说是一个挑战。四个分离的金黄色葡萄球菌对甲氧西林耐药(4/20,20%)。在我们的队列中,入住 ICU 的重症 Covid-19 患者的细菌性呼吸道合并感染率为 50%,产碳青霉烯酶的革兰氏阴性菌的发生率很高,这需要增加抗菌药物的用量,这对临床医生来说是一个挑战。四个分离的金黄色葡萄球菌对甲氧西林耐药(4/20,20%)。在我们的队列中,入住 ICU 的重症 Covid-19 患者的细菌性呼吸道合并感染率为 50%,产碳青霉烯酶的革兰氏阴性菌的发生率很高,这需要增加抗菌药物的用量,这对临床医生来说是一个挑战。
更新日期:2021-06-25
down
wechat
bug